How can we improve access to new (and old) antibiotics in australia?: It is hoped that new registration mechanisms and economic incentives will encourage much-needed drug development

Medical Journal of Australia

Volumn 199, Issue 2, 2013, Pages 81-82

  Cheng, Allen C ^a,b   Nation, Roger L ^a  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ARTESUNATE; BEDAQUILINE; CHLORAMPHENICOL; COLISTIN; ETHAMBUTOL; FOSFOMYCIN; ORPHAN DRUG; PLACEBO;

ANTIBIOTIC RESISTANCE; AUSTRALIA; BACTERIAL INFECTION; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; ECONOMIC ASPECT; EDITORIAL; GRAM NEGATIVE INFECTION; HUMAN; MALARIA; MULTIDRUG RESISTANT TUBERCULOSIS; NEPHROTOXICITY; NONHUMAN; POLICY; REGISTRATION; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; AUSTRALIA; DRUG APPROVAL; DRUG DISCOVERY; HEALTH SERVICES ACCESSIBILITY; HUMANS; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 84880682765     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja13.10657     Document Type: Editorial

References (10)

1. Gottlieb T, Nimmo GR. Antibiotic resistance is an emerging threat to public health: an urgent call to action at the Antimicrobial Resistance Summit 2011. Med J Aust 2011; 194: 281-283.
2. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
3. Boucher HW, Talbot GH, Benjamin DK Jr, et al; Infectious Diseases Society of America. 10 ×'20 progress - development of new drugs active against gramnegative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013; 56: 1685-1694.
4. Infectious Diseases Society of America. The 10 20. Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50: 1081-1083.
5. Infectious Diseases Society of America. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis 2012; 55: 1031-1046.
6. Australian Government. Therapeutic Goods Regulations 1990. (Statutory Rules 1990. No. 394.) Canberra: Commonwealth of Australia, 2012. http://www.comlaw.gov.au/Series/F1996B00406 (accessed May 2013).
7. Australian Government Department of Health and Ageing. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). Canberra: Commonwealth of Australia, 2008. http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-guidelines (accessed May 2013).
8. Avorn J. Approval of a tuberculosis drug based on a paradoxical surrogate measure. JAMA 2013; 309: 1349-1350.
9. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
10. Cheng AC, Turnidge J, Collignon P, et al. Control of fluoroquinolone resistance through successful regulation, Australia. Emerg Infect Dis 2012; 18: 1453-1460.